

Retatrutide
A triple-agonist peptide under investigation in metabolic research settings.
- Class
- GIP/GLP-1/glucagon receptor triple agonist
For research use only. Not for human or veterinary use.

Molecular data, form, and storage requirements on every compound page. No guesswork.
Supplied strictly for in vitro laboratory research — never for human or veterinary use.
Class, molecular data, and form stated plainly on every compound page.
Storage requirements on every compound page, and the full handling chain from intake to dispatch.
Packaged to protect compound integrity and shipped with tracking.
Welcome to
Every compound, documented properly.
We put the effort into describing each research compound we carry properly — class, chemistry, form, and storage requirements, on every product page.
That standard is what sets the pace here. A compound is listed once we can both ship it and tell you exactly what is known about it, including where the published evidence is preclinical or absent.
If you need a compound we do not carry, we will say so rather than substitute something close. Straight answers are the whole proposition.
MVPeptide products are supplied to qualified research professionals and institutional users for in vitro laboratory research only. These products are not drugs, foods, cosmetics, or dietary supplements, have not been evaluated by the FDA, and are not intended for human or animal use. Any such use is prohibited and may violate federal, state, or local law. We reserve the right to refuse any order that does not meet our buyer qualification criteria. By purchasing, the buyer represents and warrants that the product will be used solely for in vitro research.

Metabolic Research
Retatrutide is a synthetic peptide engineered to engage three metabolic receptor pathways (GIP, GLP-1, and glucagon receptors). It is an investigational compound with active ongoing research.
The catalog
A selection from our research catalog. Every page carries molecular data, form, and storage requirements.

Catalog additions and new compound pages, straight to your inbox. No spam.